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Background: Medication safety for older persons represents an ongoing challenge. Inappropriate prescriptions – those
with a high risk of evidence-based harm – persist in up to 25 % of seniors, and account for a significant proportion of
avoidable emergency department visits. This project is the sequel to the EMPOWER study, in which a novel consumer-
targeted written knowledge transfer tool aimed at empowering older adults to act as drivers of benzodiazepine
de-prescription resulted in a 27 % reduction of inappropriate benzodiazepine use at 6-month follow-up (number needed
to treat (NNT) = 4). Failure to discontinue in the EMPOWER study was attributable to re-emerging symptoms among
participants, prescribing inertia, and lack of knowledge and skills for substituting alternate therapy among physicians and
pharmacists. To maximize de-prescription of inappropriate therapy, educational medication-risk reduction initiatives should
be tested that simultaneously include patients, physicians and pharmacists. The objective of this trial is to: 1) test the
beneficial effect of a new de-prescribing paradigm enlisting pharmacists to transfer knowledge to both patients and
prescribers in a 2-pronged approach to reduce inappropriate prescriptions, compared to usual care and 2) evaluate the
transferability of the EMPOWER study concept to other classes of inappropriate prescriptions.
Methods: We intend to conduct a 3-year pragmatic cluster randomized parallel-group controlled trial to test the effect of
the new de-prescribing intervention compared to usual care for reducing 4 classes of inappropriate prescriptions from
the 2012 Beers criteria among 450 community-dwelling older adults with polypharmacy. Inappropriate
prescriptions will include benzodiazepines, sulfonylurea hypoglycemic agents, first generation antihistamines
and non-steroidal anti-inflammatory drugs. The study population is community-dwelling older adults recruited
from community pharmacies in Quebec, Canada. The intervention was developed based on a systematic review
of the evidence for each medication. Participants in the experimental group will receive the written educational
program following randomization and have their pharmacist send their physicians an evidence-based pharmaceutical
opinion to recommend de-prescription and be followed for a year. The control group will be wait-listed for 6 months.
Discussion: System change to effectively reduce medication risk among community-dwelling seniors requires
a coordinated approach targeting physicians, pharmacists and patients. This trial will test the feasibility and
effectiveness of a tripartite approach to de-prescribing.
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Older adults rank concerns about medication side effects
highest on their list of health priorities, with 89 % of
those with chronic conditions willing to attempt ces-
sation of one of their medications if deemed appro-
priate by a physician [1–3]. Seniors have good reason
to be concerned: as life expectancy improves and
older adults live longer with chronic conditions, they
are also more likely to consume multiple medications
[4, 5]. Polypharmacy is a risk factor for adverse drug
events including drug-drug interactions, emergency
department visits due to therapeutic competition,
hospitalization and death [6–8]. Some medications
confer greater risk than others, and are termed in-
appropriate when their risks outweigh the benefits,
and when safer therapeutic alternatives exist that have
similar or superior efficacy [9–11].
Despite the development of guidelines identifying in-
appropriate medications among older adults such as the
Beers criteria [9], inappropriate prescriptions persist in
up to 25 % of community-dwelling non-hospitalized
older adults aged 65+, depending on the criteria used
and the country studied [10, 12]. Interventions aimed at
physicians and pharmacists for reducing inappropriate
medication use include medication reviews and software
alerts [13, 14]. In a previous study [15], we developed
and tested a consumer-targeted written knowledge
transfer tool aimed at empowering older adults to act as
drivers of safer prescribing practices. This resulted in a
27 % discontinuation rate in the intervention group in-
dependent of patient factors [15] and thus EMPOWER
provided proof of concept that directly targeting con-
sumers as drivers of safer prescriptions can be effective
for reducing medication risk.
Several challenges and opportunities became apparent
in the EMPOWER study. Patients stated in 33 % of cases
that physicians were reluctant to change their prescrip-
tion. Second, we realized that if the de-prescribing
process were to become sustainable over the longterm,
the new paradigm would have to be entrenched within
the pharmaceutical sector and involve the prescriber, the
patient and the pharmacist.
A tripartite approach to de-prescribing is supported by
a recent systematic review on the barriers of de-
prescribing, which suggests that the decision to stop a
medication by an individual is influenced by multiple
competing barriers and enablers [16]. In this review, atotal of four enablers and barriers to de-prescribing
were identified. Enablers consisted of agreement with
appropriateness of cessation, positive influences such
as support from the pharmacist and/or physician, dis-
like of medication as well as the presence of a clear
cessation process. Barriers to cessation consisted of
fear of cessation, negative influences such as discour-
agement from the pharmacist and/or physician, dis-
agreement over the appropriateness of cessation, as
well as the absence of a clear cessation process. Using
this knowledge as well as our own findings from the
EMPOWER study, which also demonstrated barriers
to cessation such as prescribing inertia and a lack of
knowledge and skills for substituting alternate therapy,
we developed the current approach to the patient de-
prescribing process. This trial aims to address these
barriers and to test the beneficial effect of enlisting
pharmacists to transfer knowledge on inappropriate





The primary objective of the trial is to evaluate the
effectiveness of a pharmacist-initiated educational know-
ledge transfer intervention to both patients and prescribers
on the discontinuation of inappropriate prescriptions on a
community-based sample of chronic inappropriate pre-
scription users as measured by the rate of targeted medica-
tion discontinuation at 6 months, with 1-year follow-up to
determine whether change rates are sustained over
the longterm. The acronym D-PRESCRIBE stands for
“Developing Pharmacist-led Research to Educate and
Sensitize Community Residents to the Inappropriate
prescription Burden in the Elderly.”
Secondary objectives of the study include: evaluating
the added benefit of implicating physicians and pharma-
cists in a patient-targeted educational intervention on
the discontinuation of inappropriate prescriptions in
comparison to the EMPOWER [15, 17] study, where
patients alone were targeted; to test the transferability of
this novel approach to inappropriate prescription dis-
continuation explored in the EMPOWER study to other
classes of inappropriate medications; to better under-
stand the mechanisms by which the educational tool
affects participants’ risk perception, knowledge and
Martin et al. Trials  (2015) 16:266 Page 3 of 11beliefs with respect to inappropriate prescription use; to
evaluate the impact of evidence-based pharmaceutical
opinions on physicians’ perception of the prescription as
inappropriate; and to document response rates and the
overall feasibility of using pharmaceutical opinions as a
clinical tool to catalyze physicians to de-prescribe in-
appropriate prescriptions.
Design
This is a pragmatic, cluster randomized, parallel-group
controlled trial. A cluster design was chosen to prevent
contamination across the intervention and control arms
by individual clients served by the same pharmacy. The
cluster and unit of randomization consists of each com-
munity pharmacy. There are two arms in this parallel-
randomized controlled trial for each of the four medica-
tion categories targeted: the educational intervention
arm and the control arm. A 50:50 ratio (intervention:
control) of participants will be used in each medication
class arm. Figure 1 illustrates the flow chart.
Study site: clusters and characteristics
The study is being conducted in the greater Montreal
area in Quebec, Canada. Collaboration was established
with the pharmacies of 3 local drugstore chains within
a 2-hour driving radius (approximately100 km) of
Montreal. Pharmacies are randomly ordered via a
computer-generated program, and subsequently in-
vited to participate in the trial in that order. Clusters
consisted of community pharmacies that are able to track
medication dispensing, that have a ≥ 20 % older person
clientele, and that consent to participate in the project.Fig. 1 Study flowchartStudy population
The study population comprises chronic users of the
four targeted classes of inappropriate prescriptions
among community-dwelling older adults recruited from
community pharmacies in Quebec.
Men and women 65 years of age and older with
chronic consumption (>3-month claims) of one of 4 tar-
geted inappropriate prescriptions classes are eligible for
participation in this trial. The choice of these 4 medica-
tion classes was based on moderate to high quality
evidence and the strength of the recommendations
presented in the 2012 Updated Beers Guidelines for
Inappropriate Prescriptions [9], as well as their frequency
of use in the general population [18–20]. There is a
strong recommendation for avoiding the four classes of
prescription medications chosen in this trial (see Table 1)
with moderate to strong evidence backing these recom-
mendations [9].
Patients with a diagnosis of severe mental illness or
dementia ascertained by the presence of an active pre-
scription for any antipsychotic medication and/or a cho-
linesterase inhibitor or memantine in the preceding
3 months, those unable to communicate in French and/
or English as well as patients showing evidence of
significant cognitive impairment (a baseline screening
score < 24 on the Mini-Mental State Exam (MMSE) [21])
are excluded. Additionally, patients in assisted-living facil-
ities will be excluded from the study population.
Ethical approval
The study protocol was approved by the Research Ethics
Board of the Centre de Recherche de l’Institut Universitaire
Table 1 Targeted medication classes
Medication class Rationale
All benzodiazepines as well as non-benzodiazepine hypnotics • Associated with:
○ A 5-fold increased risk of cognitive events [36–39]
○ A 30 % to 2-fold increased risk of falls [40–42], a 50 % increased risk of
hip fractures [42–46]
○ A 25 % to 2-fold increased risk of motor vehicle accidents [47–49]
○ Increased risk of Alzheimer’s disease by up to 80 % [50]
• Similar evidence of harm exists for non-benzodiazepine hypnotics [9]
• Hypnotics are associated with a greater than 3-fold increased risk of death
even when prescribed < 18 pills/year [51]
Anticholinergic agents including first-generation antihistamines
(as single agents or as part of combination products)
• Can cause cognitive impairment [39]





Long-acting sulfonylurea oral hypoglycemic agents chlorpropamide
or glyburide used for the treatment of diabetes
• Estimated to be responsible for 11 % of emergency hospitalizations for
adverse drug events in older adults [58]
• Glyburide is associated with a 52 % greater risk of experiencing at least
one episode of hypoglycemia compared with other secretagogues and
with 83 % greater risk compared with other sulfonylureas [59, 60]
• Chlorpropramide has potential to cause SIADH (syndrome of inappropriate
antidiuretic hormone secretion) [61]
• Glyburide was a new addition to the Beers list in 2012 [9, 62]
Chronic non-COX-selective non-steroidal anti-inflammatory drug
(NSAIDs)
• Increased risk of gastro-intestinal bleeding/peptic ulcer disease in older adults
• Ulcers, bleeding, or perforation caused by NSAIDs occur in approximately
1 % of patients treated for 3–6 months, and in about 2–4 % of patients
treated for 1 year with trends continuing with longer duration of use [63–65]
• Use of misoprostol or a proton pump inhibitor reduces this risk, it does
not eliminate it
A full list of medication associated with these drug classes is presented in Appendix 1: Table 3
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Enrollment
Enrollment in the trial was conducted in collaboration
with three regional pharmacy chains. Company head-
quarters provided the research team with a list of all
chain drugstores with an appropriate version of the
pharmacy software within a 100-km radius of the re-
search center. Following this, a high-ranking company
representative of each of the three banners circulated an
announcement to all pharmacist owners to participate in
the project. Following these announcements, pharmacy
lists were randomized and then each one contacted sys-
tematically in that order to assess interest in participa-
tion. Pharmacists interested in participating then met in
person with a research coordinator to sign a collabor-
ation engagement, thus confirming their participation in
the trial.Recruitment of participants and application of eligibility
criteria
Participants will be recruited to the trial in a systematic
fashion. Participating pharmacists will approve the ex-
traction from the pharmacy software of a comprehensive
list of all clients meeting eligibility criteria for the study,
divided according to the four targeted drug classes, and
listed in random order by drug class. An extraction algo-
rithm was developed and validated to reflect the inclu-
sion and exclusion criteria of participants for the study,
and applied across all participating pharmacies. The
pharmacist then systematically and sequentially phones
each client from each of the four drug classes to invite
them to be contacted by the research team for more
information about participating in a study on safe
medication management, to a maximum of seven con-
senting participants per drug class or until no more
names remain on the lists. The pharmacist records all
responses and transfers the names and phone numbers
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staff. Research assistants then contact all potential par-
ticipants referred by the pharmacists (with the client’s
permission), re-explains the details to confirm interest
in participation and then arrange an appointment at
the participant’s residence or at the research center
(based on patient preference) to complete the third
screening stage: signed consent if eligible and collec-
tion of baseline data. During this visit, a research as-
sistant reviews the medication currently taken by the
patient, queries the medical history and assesses cogni-
tive function. Signed informed consent to participate
in the study is then obtained from individuals who
meet the study criteria after baseline cognitive and
health status screening. This procedure is followed
until three clients from each drug class have been re-
cruited per pharmacy, or until such time as there are
no more eligible clients at that pharmacy or clusters
have been filled. Participants taking one or more of
the targeted drug classes will be randomly assigned to
only one group and receive the intervention for a sin-
gle drug class only.
Randomization
Randomization/Concealment of allocation
Randomization will be by pharmacy cluster after re-
cruitment procedures are complete for the cluster.
Randomization will be done in blocks using a 1:1 ratio
every time to pharmacies and their patients’ complete en-
rollment and baseline data collection. Allocation of the
intervention by a third party will be blinded via a
computer-generated random digit generated by a re-
search assistant not involved in participant recruitment,
as will data analysis and ascertainment of the outcome.
The trial is, nonetheless, considered open-label because
both the research assistant who delivers the interventions
and the study participants and pharmacists who receive
the educational materials will be aware that the interven-
tion is being delivered.
Blinding
As the intervention is educational in nature, blinding of
the intervention is impossible. However, to preserve a
certain level of blinding and to protect against sources
of bias, the following measures are taken. For partici-
pants, blinding is achieved by presenting the project to
participants as a project on optimizing medication man-
agement. Consenting participants understand that their
medication profiles will be transmitted to the research
team within the following months and that they will re-
ceive a customized letter at some point during the year
that may contain recommendations for change, which
they can then decide to take to their physician or
pharmacist for discussion. For pharmacists, blinding isachieved by presenting the same study timeline. Pharma-
cists are aware that their clients will receive an interven-
tion at some point during the following year and remain
blinded to group allocation throughout the course of the
study. Pharmacists also remain blinded to other partici-
pating pharmacies. Since pharmacies are randomized as
clusters, they are located in distinct geographic locations
and generally have no reason to interact with one an-
other. Thus, blinding pertains to both the individual and
cluster level.
Intervention
The intervention is multifaceted, consisting of the deliv-
ery of educational materials about inappropriate pre-
scriptions to both patients and their prescribers by the
pharmacist. The pharmacist will deliver in person or by
mailing the educational material to the patient in the
form of a written educational brochure that was devel-
oped and tested during the EMPOWER study [15]. All
educational material will be customized to the type of
inappropriate prescription being consumed by the pa-
tient. All materials have already been developed and
tested for acceptability [17]. Pharmacists will also pro-
vide a letter to their clients explaining why they are re-
ceiving an intervention, and a pamphlet inviting them to
schedule a consultation. The pharmacist will deliver the
educational material to the physician in the form of a
faxed pharmaceutical opinion 2 weeks after having deliv-
ered the intervention to patients. The research team will
provide the pharmacist with the customized educational
materials for their patients, and examples of evidence-
based pharmaceutical opinions that could be sent to the
patient’s physician depending on the type of inappropri-
ate medication consumed. The evidence-based pharma-
ceutical opinions were developed by the research team,
reviewed by experts, field-tested among a cohort of phy-
sicians as well as a team of pharmacists, and adapted
until consensus was reached on the content and format
for the final versions. The evidence-based opinions refer
to the Beers criteria and other literature detailing the
risk of harm associated with use of each targeted drug
class for older adults, and include suggestions for safer
therapeutic alternatives. The pharmacist is allowed flexi-
bility in their choice of whether to use the pharmaceut-
ical opinions provided by the research team, adapt it to
their needs, draft their own pharmaceutical opinion for
the physicians or not send out any opinion at all. All
study materials are distributed to each participating
pharmacist assigned to the intervention group immedi-
ately after randomization.
The comparator for this study will be usual care dur-
ing the 6-month time period postrandomization. Usual
care is a common comparator for a pragmatic trial, since
it captures a wide, realistic range of alternate practice
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informed that the project materials will be delivered
“sometime over the next year.” We will explain to the
pharmacists that delays with various study procedures
may take 3–6 months and that the recruitment process
for the study is long. We will request that no action be
taken by the pharmacist other than usual care until such
time as the study materials are delivered to them. The
control group pharmacists will be given all the educa-
tional materials at the end of their 6-month wait period
postrandomization.
Study follow-up
Study follow-ups include 2 telephone calls 1 week and
6 weeks post randomization, and a single in-person
interview at 6 months postintervention. Telephone inter-
views last from 5 to 10 minutes while the final in-person
interview may take up to 30 minutes.
Outcomes
Prescription discontinuation rates at 6 months
The primary outcome for the trial is discontinuation of
any of the targeted inappropriate prescriptions. The time
period for ascertainment of the outcome is 6-months
post-intervention. The 6-month time period was selected
according to data obtained in the EMPOWER study and
is consistent with the transtheoretical model of change,
which predicts that once people start thinking about
changing their behavior they usually make a decision
and implement their plan of action within 6 months
[23]. A follow-up at 1 year will be obtained to monitor
long-term changes and to assess whether discontinu-
ation persists.
Outcomes will be measured from the administrative
database used for public drug claims reimbursement for
both the intervention and control groups. This database
includes all prescriptions filled at the pharmacy as well
payment claims to pharmacists for all services rendered,
such as the delivery of pharmaceutical opinions to physi-
cians. Prescription data contain information on all dis-
pensed prescriptions including drug name, dispensation
date, dosage, drug form, duration and quantity of the
drug dispensed, as well as the license number of the
physician who wrote the prescription. Discontinuation
of an inappropriate prescription will be defined as the
lack of a claims renewal for that medication during a
minimum of 3 or more consecutive months (with no
subsequent renewals) as well as the absence of initiation
of another inappropriate prescription of the same class.
Secondary outcomes
Medical Research Council guidance for complex inter-
vention studies recommends that process evaluations be
conducted within the trial to assess the fidelity andquality of implementation of the intervention, to clarify
causal mechanisms, and to identify contextual factors
associated with variation in outcomes [24]. We therefore
intend to track the sequence of events stemming from
the delivery of the knowledge transfer tools to each
pharmacist in the intervention group. The following
parameters will be measured:
 Delivery of the educational brochures to the patients
by their pharmacists
 Prevalence, timing and type of pharmaceutical
opinions sent by the pharmacists to the patients’
primary care providers
 Effect of the patient knowledge transfer tool on
patients’ beliefs about the use of their inappropriate
medications and their intent to discuss cessation
with their doctor or pharmacist
 Effect of the pharmaceutical opinion on the
prescriber’s behavior
 Patient-physician encounters to discuss inappropriate
prescriptions
 Patient self-efficacy and improvement in self-efficacy
in ability to change medication
Table 2 illustrates the time points for measurement of
each outcome during the study.
Sample size
The main question driving the sample size is whether
the delivery of a knowledge transfer intervention by
pharmacists to consumers of inappropriate prescriptions
and their prescribers is more likely to result in discon-
tinuation of inappropriate prescription over a 6-month
time period compared to usual care. We hypothesize
that our intervention will achieve a rate of discontinu-
ation that is at least as great as that achieved in previ-
ous studies by medication review by a pharmacist and
contact with a physician (maximum rate 27 % in
EMPOWER [15]) compared to usual care (maximum
rate of discontinuation 6 %) [13, 14, 18, 25–29]. These
figures were derived from published studies in older
people conducted in the community setting with a
non-imposed intervention targeting inappropriate pre-
scriptions, and included a prescription discontinuation
measure. We therefore intend to power our study to
detect a minimal 20 % increase in any inappropriate
medication discontinuation over usual care, and an ab-
solute minimal rate of discontinuation of 25 %, which
would compare to EMPOWER. We are also interested
in conducting sub-group analyses by drug class as the
four drug classes we have chosen have different indi-
cations and may have different rates of discontinuation
due to the intervention. Our calculations also account
for the cluster design, with adjustments made for both
Table 2 Overview of data collection and measurements in both
trial arms
Baseline Follow-up
Visit number T0 T1 T2 T3












Blood glucose monitoring Xc Xc Xc





Medication risk assessment X X
BMQ-Specific X X







BMQ-Specific, Beliefs about Medicines Questionnaire - Specific segment [66];
DTSQs, Diabetes Treatment Satisfaction Questionnaire [67]; MMSE, Mini-Mental
State Exam [68]; PATD, Patients Attitude Towards De-prescribing Questionnaire
[69]; SF-12, 12-Item Short Form Survey to measure health status and health-related
quality of life [70]; VES-13, Vulnerable Elders Survey [71]. aOnly administered if in
benzodiazepine group
bOnly administered if benzodiazepine tapering had begun
cOnly administered if in sulfonylurea group
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We assume that the intracluster correlation coefficient
(ICC) will be similar to the ICC observed in the
EMPOWER study (0.008) [31]. Based on pilot work
from EMPOWER [17], we have chosen the minimal
number of participants per drug class (n = 3) in order
to augment the likelihood that each consenting phar-
macy will achieve the required number of participants.
Limiting the number of participants per pharmacy and
per drug class should also lower design effects when
compared to the EMPOWER study where clusters var-
ied from 2 to 27 participants per pharmacy [30]. With
an estimated ICC of 0.05 (worst-case scenario) for the
3 participants recruited per drug class, we would re-
quire 17 pharmacies per group (51 participants per
arm) to be able to estimate a 20 % absolute discon-
tinuation rate difference between trial arm by drug
class with 80 % power and alpha 0.05 [31]. To detect
greater differences, a lower sample size is needed.
Thus we would have ample power for the overall com-
parison. Based on preliminary recruitment rates forthe D-PRESCRIBE trial during a run-in period, we
have observed that only 1 out of every 10 pharmacies
that participate are able to recruit the desired number
of participants with a participant range per pharmacy
of 3–12 and a mean of 6 participants per pharmacy.
This may be because smaller pharmacy chains are eli-
gible for inclusion, compared to the EMPOWER trial.
Based on our previous research we assume that 10 %
of participants will withdraw or be lost to follow-up.
We have, therefore, inflated our sample size to 450
participants (112 per medication class) from an esti-
mated 75 pharmacies. Additionally, to compare the
added benefit of the pharmaceutical opinion in com-
parison to the educational material alone, we chose to
recruit an additional three participants from the
benzodiazepine group. This was powered to detect a
minimal 12.5 % difference between participants in this
study and the EMPOWER study and accounted for
the previously mentioned sample size considerations.
Analysis
To determine whether randomization was effective,
descriptive statistics (means, proportions) will be cal-
culated to assess the balance between the groups on
important confounders such as age, sex, health sta-
tus, baseline beliefs about medications and the degree
of polypharmacy. The primary analysis will focus on
answering the main research question driving this
study - whether the intervention results in an increased
discontinuation rate of inappropriate prescriptions of at
least 20 % compared to usual care. We will use a mar-
ginal model estimated via generalized estimating equa-
tions (GEE) with a binary outcome and an identity link,
with an exchangeable correlation structure to account for
correlation between participants in the same cluster. Par-
ticipants will be analyzed as randomized (ie, intention to
treat). Risk differences between the control and experi-
mental groups will be calculated and the robust variance
estimator will be used to estimate the associated 95 %
confidence interval and P-value [32]. If any confounders
(age, sex, degree of polypharmacy or health status) are
unbalanced between the groups, we will estimate the
unadjusted and adjusted odds ratios for the interven-
tion via a marginal model estimated via GEE with an
exchangeable correlation structure. The robust vari-
ance estimator will again be used. All analyses de-
scribed above will be repeated for each drug class
during sub-analysis. As a sensitivity analysis, we will
compare results obtained with the GEE to other pro-
cedures that account for clustering such as general-
ized linear mixed models.
The fidelity and quality of implementation of the inter-
vention by the pharmacists will be assessed by rates of
delivery of the educational materials to the participants
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ceutical opinions delivered and the patients’ and physi-
cians’ responses to receipt of the knowledge transfer
tools will be reported as proportions, along with 95 %
confidence intervals, and will be stratified by type of pre-
scription. In order to determine whether the patient
intervention altered beliefs about the necessity-concern
ratio for the inappropriate prescriptions, linear mixed
models will be used to evaluate change-scores pre-
intervention and postintervention for each medication
class with the pharmacist as a random effect. To better
understand the explanatory mechanisms driving the suc-
cess or failure of the intervention, we will track the se-
quence of events following randomization for each
patient in the intervention group. The chronological
order of billings for pharmaceutical opinions, pre-
scription changes, and patient visits to the physician
for each participant and each type of prescription
will be ascertained. These will be compared to the
dates and content of the response cards returned by
the physicians and the patients’ reports of what tran-
spired during any discussions with health providers
about their medication. Analysis of these temporal
“pathways” will provide valuable insight into how and
why the de-prescribing process occurred or did not
occur for each participant.
Discussion
The EMPOWER study demonstrated that direct-to-
consumer education is effective at eliciting shared
decision-making around the overuse of medications that
increase the risk of harm in older adults. Our hope here
is to demonstrate the added value of using pharmacists
as a bidirectional conduit of evidence-based knowledge
to patients and physicians to drive the reduction of in-
appropriate prescriptions. In various countries, legisla-
tive and regulatory changes have led to a wider scope of
pharmacist practice for substituting or discontinuing
certain medications [27]. Data from randomized trials
indicate that patients benefit from increased pharmacist
involvement in their care [33].
The patient-centered process developed for this study
aims to reinforce known enablers and address barriers to
medication cessation. By providing the patient with
evidence-based information in the educational brochures
we expect to increase patient’s endorsement of appropri-
ate cessation, increase their dislike of the medication, re-
duce the fear of re-emerging symptoms, and equip them
with the skills to safely taper their medication. Patient
empowerment is a key mechanism for increasing patient
responsibility in shared decision-making with health care
providers [34]. Use of an evidence-based pharmaceutical
opinion aims to catalyze and support pharmacists and
physicians by providing them with the appropriate toolsand information to positively influence and encourage
patients to initiate de-prescribing. Only 41 % of commu-
nity pharmacists admit familiarity with the Beers criteria
of drugs to avoid in older people [35]. As such, the
evidence-based pharmaceutical opinion serves a dual
purpose in educating both pharmacists and physicians
about the latest pharmacogeriatric recommendations.
This tripartite educational approach to pharmacists,
physicians and patients is intended to achieve synergistic
impact.
Strengths
Strengths of the study include but are not limited to its
pragmatic design, which will allow the observed process
to reflect real world practice as accurately as possible.
Systematic recruitment of participants via community
pharmacies, blinding of the study hypothesis from par-
ticipants, physicians, pharmacists, and evaluators as
well as objective assessment of drug discontinuation
rates from pharmacy prescription renewal profiles will
increase the trial’s internal validity. Comparison with
EMPOWER and other studies will allow us to examine
the synergic effects of our intervention compared to
direct-to-consumer and direct-to-prescriber interven-
tions alone. Additionally, a comparison of discontinu-
ation rates for the four different drug classes may
allow us to identify different barriers and/or enablers
that need to be addressed for different medication
indications.
Limitations
Limiting the list of inappropriate medications to four
drug classes only will restrict the study’s potential
generalizability to all inappropriate prescription. Con-
tamination between the experimental and control groups
is possible, but we expect it to be minimal. Pharmacists
will be informed that the intervention will be staggered
over the course of a year and they should follow usual
care until receipt of the study materials. Physicians may
end up with patients in both the control and experi-
mental arms of the study, but this is unlikely as phar-
macies generally serve a specific geographic area and
patients will be recruited throughout Quebec. The
physician will not be contacted directly because of the
potential to influence the outcome of the intervention
during the study period and/or to interfere with the
pharmacist-doctor relationship. Information on what
occurs during the physician-patient encounter will, there-
fore, be limited.
Trial status
The trial is currently recruiting participants and is ap-
proximately 60 % complete at the time of publication.
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Benzodiazepines First generation antihistamines Long-acting sulfonylurea Non-COX-selective NSAIDs
Alprazolam Hydroxyzine Chlorpropamide Aspirin (>325 mg/day)







Chlordiazepoxide-amitriptyline Dexchlorpheniramine Mefenamic acid








D-PRESCRIBE: Developing Pharmacist-led Research to Educate and Sensitize
Community Residents to the Inappropriate prescription Burden in the Elderly;
GEE: generalized estimating equations; ICC: intracluster correlation coefficient;
MMSE: Mini-Mental State-Exam; NSAIDs: non-steroidal anti-inflammatory
drugs.
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